首页> 外文期刊>Molecular and Cellular Endocrinology >Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
【24h】

Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.

机译:使用选择性抑制剂在三种乳腺癌细胞系中相对地参与了三种17β-羟基类固醇脱氢酶(1、7和12型)的雌二醇形成。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We investigated the relative involvement of three reductive 17beta-hydroxysteroid dehydrogenase (17beta-HSD) isoforms, namely types 1, 7 and 12, in the formation of potent estrogen estradiol (E2) in 10 human breast cancer cell lines (T-47D, MCF-7, ZR-75-1, CAMA-1, BT-20, BRC-17, BRC-31, BRC-32, BRC-36 and BRN-196) and also in 1 choriocarcinoma cell line (JEG-3) using selective inhibitors. In T-47D, BT-20 and JEG-3 cells, a 17beta-HSD1 inhibitor almost completely inhibited the formation of E2 at 1microM from 60nM of estrone (E1) (98%, 91% and 90%, respectively), whereas no significant inhibition of E2 formation was obtained using inhibitors of types 7 and 12. However, we obtained lower levels of inhibition (32%, 36% and 35% respectively using inhibitors of types 1, 7 and 12 at 10microM) in MCF-7 cells and even lower and variable levels of inhibition (15%, 23% and 18% respectively using inhibitors of types 1, 7 and 12 at 10microM) in ZR-75-1 cells. No inhibition of E2 formation was observed in CAMA-1 cells with a 17beta-HSD1 inhibitor at 1microM whereas inhibitors of types 7 and 12 inhibited 40% and 30% of E2 formation, respectively. In BRC and BRN cell lines, types 1, 7 and 12 17beta-HSDs were all involved in the formation of E2, but type 12 seemed to predominate. At 10microM, each inhibitor inhibited 10-50% of the formation of E2. Using MCF-7 and BRC-32 cell lines, a combination of the three inhibitors (3x10microM) does not fully inhibit the 17beta-HSD activity (65% and 75%). In addition to identify the relative importance of types 1, 7 and 12 17beta-HSDs in the formation of E2 in human breast cancer cell lines, our results show also a great variability between each cell line. In some cases the formation of E2 was completely inhibited, but this was not the result observed in other cell lines, suggesting the presence of another enzyme involved in the biosynthesis of E2.
机译:我们调查了三种还原性17β-羟类固醇脱氢酶(17β-HSD)亚型,即1、7和12型,在10种人类乳腺癌细胞系(T-47D,MCF)中形成强效雌激素(E2)的相对参与-7,ZR-75-1,CAMA-1,BT-20,BRC-17,BRC-31,BRC-32,BRC-36和BRN-196)以及在1个绒癌细胞系(JEG-3)中使用选择性抑制剂。在T-47D,BT-20和JEG-3细胞中,一种17beta-HSD1抑制剂几乎完全抑制了60nM雌酮(E1)中1microM处E2的形成(分别为98%,91%和90%),而没有使用7型和12型抑制剂可显着抑制E2的形成。但是,在MCF-7细胞中,我们获得了较低的抑制水平(使用10、1M型的7、12和12型抑制剂分别抑制了32%,36%和35%)甚至在ZR-75-1细胞中的抑制水平更低(包括15 microM,1、7和12型抑制剂分别为15%,23%和18%)。在1microM处使用17beta-HSD1抑制剂的CAMA-1细胞中未观察到E2形成的抑制作用,而7型和12型抑制剂分别抑制了E2形成的40%和30%。在BRC和BRN细胞系中,类型1、7和12的17beta-HSD都参与了E2的形成,但是类型12似乎占主导。在10 microM时,每种抑制剂均抑制E2形成的10-50%。使用MCF-7和BRC-32细胞系,三种抑制剂(3x10microM)的组合不能完全抑制17beta-HSD活性(65%和75%)。除了确定类型1、7和12 17beta-HSD在人乳腺癌细胞系E2形成中的相对重要性外,我们的结果还显示了每种细胞系之间的巨大差异。在某些情况下,E2的形成被完全抑制,但这不是在其他细胞系中观察到的结果,表明存在与E2的生物合成有关的另一种酶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号